Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Pocock

Showing results (71-80 of 245) with videos related to

Pageof 25
Sort By:
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
European Heart Journal|November 13, 2008
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failurePutte Abrahamsson, Joanna Dobson, Christopher B Granger, et al.
JACC. Heart Failure|May 30, 2020
Use of the Win Ratio in Cardiovascular TrialsJoão Pedro Ferreira, Pardeep S Jhund, Kévin Duarte, et al.
Journal of the American Heart Association|June 15, 2026
Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MEDDavid E Kandzari, Felix Mahfoud, Raymond R Townsend, et al.
European Journal of Heart Failure|January 11, 2020
Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunctionPatrick Rossignol, Kevin Duarte, Nicolas Girerd, et al.
Journal of the American College of Cardiology|November 18, 2017
Predicting Subclinical Atherosclerosis in Low-Risk Individuals: Ideal Cardiovascular Health Score and Fuster-BEWAT ScoreJuan Miguel Fernández-Alvira, Valentín Fuster, Stuart Pocock, et al.
Journal of the American College of Cardiology|December 16, 2017
Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk FactorsLeticia Fernández-Friera, Valentín Fuster, Beatriz López-Melgar, et al.
European Journal of Heart Failure|January 27, 2009
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programLarry A Allen, G Michael Felker, Stuart Pocock, et al.
Journal of Hypertension|June 28, 2019
Associations between change in blood pressure and functional outcome, early events and death: results from the Efficacy of Nitric Oxide in Stroke trialElse C Sandset, Jason P Appleton, Eivind Berge, et al.
Circulation. Cardiovascular Interventions|May 20, 2025
Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED TrialDavid E Kandzari, Felix Mahfoud, Raymond R Townsend, et al.
Pageof 25

Showing results (71-80 of 245) with videos related to

Sort By:
Pageof 25
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
European Heart Journal|November 13, 2008
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failurePutte Abrahamsson, Joanna Dobson, Christopher B Granger, et al.
JACC. Heart Failure|May 30, 2020
Use of the Win Ratio in Cardiovascular TrialsJoão Pedro Ferreira, Pardeep S Jhund, Kévin Duarte, et al.
Journal of the American Heart Association|June 15, 2026
Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MEDDavid E Kandzari, Felix Mahfoud, Raymond R Townsend, et al.
European Journal of Heart Failure|January 11, 2020
Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunctionPatrick Rossignol, Kevin Duarte, Nicolas Girerd, et al.
Journal of the American College of Cardiology|November 18, 2017
Predicting Subclinical Atherosclerosis in Low-Risk Individuals: Ideal Cardiovascular Health Score and Fuster-BEWAT ScoreJuan Miguel Fernández-Alvira, Valentín Fuster, Stuart Pocock, et al.
Journal of the American College of Cardiology|December 16, 2017
Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk FactorsLeticia Fernández-Friera, Valentín Fuster, Beatriz López-Melgar, et al.
European Journal of Heart Failure|January 27, 2009
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programLarry A Allen, G Michael Felker, Stuart Pocock, et al.
Journal of Hypertension|June 28, 2019
Associations between change in blood pressure and functional outcome, early events and death: results from the Efficacy of Nitric Oxide in Stroke trialElse C Sandset, Jason P Appleton, Eivind Berge, et al.
Circulation. Cardiovascular Interventions|May 20, 2025
Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED TrialDavid E Kandzari, Felix Mahfoud, Raymond R Townsend, et al.
Pageof 25